Related Experiment Video
Updated: Jul 22, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
CDC42-A promising immune-related target in glioma
Tao Jiang1,2, Xianwei Wang1, Jiaming Huang1
1Department of Neurosurgery, The Dalian Municipal Central Hospital, Dalian, China.
Abstract:
Glioma is the worst prognostic neoplasm in the central nervous system. A polarity-regulating GTPase in cells, known as cell division cycle 42 (CdC42), has been proven to have its overactivation tightly connected to high tumor malignancy. The RNA-seq and protein expression of CDC42 in tumor and comparison tissues were analyzed based on the online tools; CDC42 was remarkably boosted in tumor tissues compared to normal controls. A total of 600 patients in the analysis set from The Cancer Genome Atlas (TCGA) database and 657 patients in the validation set from the Chinese Glioma Genome Atlas (CGGA) database were adopted. The expression of CDC42 in clinical features and biological functions of glioma was analyzed, including differential expression analysis, survival analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and immune infiltration analysis. The enrichment of CDC42 was shown to be strongly associated with poor prognosis and terrible clinical indexes of glioma, including higher World Health Organization scale grade, wild-type isocitrate dehydrogenase 1 expression, O6-methylguanine-DNA methyltransferase non-methylated status, and 1p19q non-codeletion status (p < 0.0001). Functional enrichment analysis showed that CDC42 was highly correlated with immune and inflammatory responses in glioma. Additionally, the concentration extent of CDC42 was closely related to immune infiltration, immune checkpoints, and regulatory T (Treg) cell markers (CD4, CD25, and CD127). All evidence suggested that CDC42 may be a potential target for glioma immunotherapy.
Insights
Cell division cycle 42 (CDC42) is overactivated in glioma, correlating with poor prognosis and higher tumor malignancy. Targeting CDC42 may offer a new avenue for glioma immunotherapy.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioma is a severe central nervous system neoplasm with poor prognosis.
- Overactivation of cell division cycle 42 (CDC42), a polarity-regulating GTPase, is linked to increased tumor malignancy in various cancers.
Purpose of the Study:
- To investigate the role and prognostic significance of CDC42 expression in glioma.
- To explore the association of CDC42 with clinical features, biological functions, and immune infiltration in glioma.
Main Methods:
- Analysis of CDC42 RNA-seq and protein expression data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases.
- Differential expression analysis, survival analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and immune infiltration analysis were performed.
- Correlation analysis with clinical parameters, including WHO grade, IDH1 status, MGMT methylation, and 1p19q codeletion.
Main Results:
- CDC42 expression was significantly upregulated in glioma tissues compared to normal controls.
- Elevated CDC42 levels were strongly associated with poor prognosis and adverse clinical indicators (higher WHO grade, wild-type IDH1, unmethylated MGMT, non-codeleted 1p19q).
- CDC42 enrichment correlated with immune and inflammatory responses, immune checkpoints, and regulatory T cell markers (CD4, CD25, CD127).
Conclusions:
- CDC42 is a potential biomarker for predicting poor prognosis in glioma.
- CDC42 plays a role in regulating the tumor immune microenvironment in glioma.
- CDC42 represents a promising therapeutic target for glioma immunotherapy.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation